iPS- #1 Breakthrough of 2008 Now at Allele!

Hailed as Science Magazine’s “#1 Breakthrough of the Year” for 2008, induced pluripotent stem (iPS) cell research is proving to be the most promising means of worldwide disease comprehension and eradication since the discovery of penicillin. iPS research is moving fast and institutions are racing to make the coveted advancements to: reveal the triggering and oppressing mechanisms of the four pluripotency inducing genes, elucidate how a cell is assigned a role by investigating cell protein signaling pathways, and reduce possible side effects like cancerous tumors at iPS cell therapy sites. As an in vitro reagent, iPS cells, unlike human cell lines, can be easily maintained in the lab. By maintaining iPS cell lines from patients with diseases like Parkinson’s it is possible for researchers to examine disease pathology in an affected living cell in ways that cannot be done with in vivo cells. Thanks to induced pluripotency, these cell lines can be created with simple, non-invasive hair follicle procurements! Additionally, juxtaposed to the 10 years of controversy following the discovery of human embryonic stem cells, induced pluripotent stem cells will not elicit the same moral or bioethical dilemmas followed by political interference due to their fully developed origin.

Author of Breakthrough of the Year: Reprogramming Cells, Gretchen Vogel stated, “…several more breakthroughs are needed before cellular reprogramming yields its first cure for disease.” Researchers must take advantage of Allele Biotech’s ground-breaking iPS product line. Our scientists have done all the preliminary work to design and construct these easy to use iPS kits to make this phenomenal field of study accessible to all. The global challenge for iPS discovery has begun!

Be Sociable, Share!

Tags: , , , , , , , ,

Friday, April 17th, 2009 iPSCs and other stem cells

No comments yet.

Leave a comment

You must be logged in to post a comment.